Levodopa–Carbidopa Intestinal Gel in Patients with Parkinson’s Disease : A Systematic Review
Background: Levodopa–carbidopa intestinal gel (LCIG) is available in several countries for the treatment of advanced levodopa-responsive Parkinson’s disease (PD) with severe motor fluctuations and dyskinesia when other treatments have not given satisfactory results. Objective: Our objective was to summarize the present evidence base for LCIG therapy through a systematic review of the literature. M